High-dose rate brachytherapy is one of the most effective tools available for treating gynecological cancers, delivering radiation directly at the tumor site while sparing surrounding healthy tissue. At Gulf International Cancer Center, this approach has been used in more than 500 cases, making it one of the center's most established and focused treatment specialties. For patients newly diagnosed with cervical or uterine cancer, understanding how this treatment works can make the road ahead feel far less uncertain.
Unlike external beam radiation, which delivers radiation from outside the body, brachytherapy places a radioactive source directly inside or next to the tumor for a short period. High-dose rate (HDR) brachytherapy delivers this radiation in a concentrated dose over minutes rather than days, allowing for shorter treatment sessions with precise targeting. The "high-dose rate" refers to how quickly the radiation is delivered once the source is in place, as opposed to older low-dose techniques that required patients to stay in hospital for extended periods.
Cancers such as cervical and uterine cancer are often accessible in ways that allow radioactive applicators to be placed directly within or near the tumor. This proximity lets clinicians deliver a high dose to cancerous tissue while significantly limiting exposure to the bladder, bowel, and other nearby organs.
HDR brachytherapy is frequently used alongside external beam radiotherapy as part of a combined treatment plan. External radiation treats a broader region, while brachytherapy delivers an intensified boost to the primary tumor site, a combination that has become a standard of care for many gynecological cancers, particularly locally advanced cervical cancer.
Because HDR brachytherapy concentrates a therapeutic dose into a short session, it typically requires far fewer visits than a comparable course of external radiation alone. This can meaningfully reduce the overall time a patient spends in active treatment, which matters both physically and emotionally during cancer care.
Treatment typically involves a short procedure to place the applicator, performed under anesthesia or sedation for comfort, followed by imaging to confirm positioning before the radiation dose is delivered. Sessions are usually completed on an outpatient or short-stay basis, and most patients require only a small number of sessions, often spaced a week apart, compared to weeks of daily external radiation.
Most patients experience mild, temporary side effects such as fatigue, cramping, or irritation in the treated area. Because the radiation is so precisely localized, side effects are generally more limited than with broader radiation approaches, and most patients return to normal activities within a few days of each session.
With over 500 brachytherapy cases treated, GICC's radiation oncology team has developed deep, focused experience in gynecological cancer care. This volume allows the center to refine applicator selection, dosing, and imaging protocols specifically for the anatomy and needs of gynecological cancer patients, supported by the same PET/CT and radiation oncology infrastructure that guides diagnosis and planning.
It is most commonly used for cervical, uterine, and other gynecological cancers, though it can treat other cancer types as well.
Applicator placement may cause some discomfort, which is managed with anesthesia or sedation, and the radiation delivery itself is not felt.
This varies by cancer type and stage, but it is typically delivered over a small number of sessions rather than daily treatment for weeks.
It is often combined with external beam radiotherapy to treat both the surrounding area and the primary tumor site.
Most patients report mild, short-term effects such as fatigue or localized irritation, which typically resolve within a few days.
In many cases yes, though this depends on the specific procedure and your care team's recommendation.
GICC has treated more than 500 brachytherapy cases, with a particular focus on gynecological cancers.
GICC Team has dedicated their career to improving cancer care and fostering innovative approaches to patient treatment.
All blog posts